4 completed, 1 active not recruiting, 1 recruiting, 1 terminated. 2 Phase 2, 1 Not applicable, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Not applicable | 1 | Terminated 1 |
| Phase 3 | 1 | Completed 1 |
| Phase 4 | 1 | Completed 1 |
Follow HIV-2 Infection: new trials by email Literature Review of HIV-2 Infection trials Research Report on HIV-2 Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands HIV Infections, HIV-1-infection | Active not recruiting | Erasmus Medical Center | 35 | 2021-05-26 | 2024-02-13 | |
| Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol Access HIV_blood donor, Access HIV_Hospitalized patient, Access HIV_known HIV-1 antibody positives - HIV I Infection, HIV-2 Infection | Completed | Beckman Coulter, Inc. | 8650 | 2019-12-04 | 2025-03-19 | |
| RESIST-2: 2nd-line ART for HIV-2 Infection HIV-2 Genotypic Drug Resistance Testing using DBS, 2nd line ART ( Zidovudine 300mg BID + Lamivudine 150mg BID or Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID), 2nd line ART (Tenofovir DF 300mg QD + Lamividine 300mg QD or Emtricitabine 200mg QD + Lopinavir/Ritonavir 400/100mg BID + Raltegravir 400mg BID ) - HIV-2 Infection | Not applicable | Terminated | University of Washington | 152 | 2018-07-04 | 2021-01-25 |
| First-Line Treatment for HIV-2 Tenofovir + Emtricitabine or Lamivudine + Zidovudine, Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir, Tenofovir + Emtricitabine or Lamivudine + Raltegravir - HIV-2 Infection | Phase 2 / Phase 3 | Completed | ANRS, Emerging Infectious Diseases | 210 | 2016-01-26 | 2019-07-22 |
| An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks - HIV-2 Infection | Phase 4 | Completed | University of Washington | 30 | 2014-09-01 | 2018-07-26 |
| Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients emtricitabine / tenofovir disoproxil fumarate / raltegravir . - HIV-2 Infection | Phase 2 | Completed | ANRS, Emerging Infectious Diseases | 30 | 2012-07-01 | 2026-04-02 |
| Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV HIV Infections, HIV-1-infection | Recruiting | Erasmus Medical Center | 40 | 2012-01-01 | 2024-02-14 | |
| Cohorte Nationale VIH-2 Antiretroviral - HIV-2 Infection | Unknown | ANRS, Emerging Infectious Diseases | 1185 | 1994-01-01 | 2020-12-08 |
HIV Infections (2) · Virus Diseases (1)
Infections (3) · Blood-Borne Infections (2) · Communicable Diseases (2) · Genital Diseases (2) · Immune System Diseases (2) · Immunologic Deficiency Syndromes (2) · Lentivirus Infections (2) · RNA Virus Infections (2) · Retroviridae Infections (2) · Sexually Transmitted Diseases (2) · Sexually Transmitted Diseases, Viral (2) · Urogenital Diseases (2) · Virus Diseases (2)
Emtricitabine (3) · Raltegravir Potassium (3) · Tenofovir (3) · Lamivudine (2) · Lopinavir (2) · Ritonavir (2) · Zidovudine (2) · Anti-Retroviral Agents (1) · BID protein, human (1) · Cobicistat (1) · Darunavir (1) · Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1) · elvitegravir (1)
ANRS, Emerging Infectious Diseases (3) · Erasmus Medical Center (2) · University of Washington (2) · Beckman Coulter, Inc. (1)
France (3) · Senegal (3) · Netherlands (2) · Burkina Faso (1) · Côte d’Ivoire (1) · Togo (1)
Casper Rokx, MD PhD (2) · Geoffrey S Gottlieb, MD PhD (2) · Moussa Seydi, MD (1) · Sophie Matheron, Pr (1) · Tokameh Mahmoudi, PhD (1)
PMID 29590335, PMID 29672676, PMID 34922614, PMID 38740027
R01AI120765 (1)